Amylyx Pharmaceuticals, Inc.
AMLX
$14.44
-$0.44-2.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 27.61M | 21.21M | 19.86M | 27.22M | 22.12M |
| Gross Profit | -27.61M | -21.21M | -19.86M | -27.22M | -22.12M |
| SG&A Expenses | 16.17M | 15.39M | 16.17M | 15.64M | 15.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.78M | 36.61M | 36.03M | 42.86M | 37.80M |
| Operating Income | -43.78M | -36.61M | -36.03M | -42.86M | -37.80M |
| Income Before Tax | -41.28M | -32.95M | -34.39M | -41.44M | -35.91M |
| Income Tax Expenses | -- | 46.00K | -- | -- | -- |
| Earnings from Continuing Operations | -41.28M | -33.00M | -34.39M | -41.44M | -35.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.28M | -33.00M | -34.39M | -41.44M | -35.91M |
| EBIT | -43.78M | -36.61M | -36.03M | -42.86M | -37.80M |
| EBITDA | -43.68M | -36.50M | -35.91M | -42.72M | -37.65M |
| EPS Basic | -0.37 | -0.30 | -0.37 | -0.46 | -0.42 |
| Normalized Basic EPS | -0.23 | -0.22 | -0.23 | -0.29 | -0.26 |
| EPS Diluted | -0.37 | -0.30 | -0.37 | -0.46 | -0.42 |
| Normalized Diluted EPS | -0.23 | -0.22 | -0.23 | -0.29 | -0.26 |
| Average Basic Shares Outstanding | 110.56M | 109.84M | 93.33M | 89.14M | 85.70M |
| Average Diluted Shares Outstanding | 110.56M | 109.84M | 93.33M | 89.14M | 85.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |